PHARMING GROUP NV - ADR
PHARNASDAQ🏆 #2445 by market capUS Equity
$11.79▼ $0.02 (−0.17%)
Live1h▼ 0.9%
24h▼ 0.2%
7d▲ 12.1%
14d▼ 17.4%
30d▼ 17.4%
1y▼ 2.6%
🏦Market Cap
$8.34B
Small Cap
📈Revenue Growth (YoY)
+15.2%
Healthy
📊Gross Margin
88.2%
High
💵FCF Margin
15.1%
Healthy
⚖️P/S Ratio
2.1x
Cheap
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $11.68 – $11.85
- 52-Week Range
- $0.83 – $1.82
- Volume
- $5.83B
- Avg Volume
- $5.25B
- Shares Outstanding
- 707.8M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $320M
- Last Q Revenue
- $81M
- P/E Ratio
- 63.5
- P/S Ratio
- 2.1x
- EPS (TTM)
- $0.02
- Dividend Yield
- —
Why Investors Own PHAR
- ✓High-growth profile — revenue up +57.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$320M▲ +62.9% YoY
Gross Margin (TTM)
55.5%▲ +2.7% YoY
Operating Income (TTM)
$103M▲ +62.9% YoY
Free Cash Flow (TTM)
$30M▲ +62.9% YoY
About PHARMING GROUP NV - ADR
A company profile for PHARMING GROUP NV - ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
68/100
Analyst Price Target
ⓘAverage Target
$14.96
▲ +26.9% Upside
High Target$17.52
Low Target$12.25
Based on 25 analysts
Latest News & Updates
🚀
Reuters·2h ago
PHARMING GROUP NV - ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift PHAR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
PHARMING GROUP NV - ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.